| Ranked All-Publication list | Historiographs | Glossary HistCite Guide About |
| Nodes: 157, Authors: 651, Journals: 56, Cited References: 4978, Words: 575
Yearly output | Document Type | Language | Institution | Institution with Subdivision | Country |
| View: Overview | Sorted by NCR. |
Page 1 of 2: [ 1 2 ]
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
|---|---|---|---|---|---|
| 1 | 2 | 363 | 137 2006 MAYO CLINIC PROCEEDINGS 81 (1): 104-130 Steensma DP; Bennett JM The myelodysplastic syndromes: Diagnosis and treatment | 0 | 2 |
| 2 | 1 | 232 | 71 2006 BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY 19 (3): 365-385 Tefferi A; Gilliland G Classification of chronic myeloid disorders: From Dameshek towards a semi-molecular system | 0 | 0 |
| 3 | 19 | 229 | 154 2006 SEMINARS IN THROMBOSIS AND HEMOSTASIS 32 (4): 307-340 Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; et al. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders | 0 | 0 |
| 4 | 38 | 212 | 96 2006 BRITISH JOURNAL OF HAEMATOLOGY 134 (4): 366-384 Khwaja A The role of Janus kinases in haemopoiesis and haematological malignancy | 0 | 0 |
| 5 | 1 | 208 | 44 2005 MAYO CLINIC PROCEEDINGS 80 (9): 1220-1232 Tefferi A; Barbui T bcr/abl-negative, classic myeloproliferative disorders: Diagnosis and treatment | 1 | 3 |
| 6 | 1 | 200 | 37 2005 JOURNAL OF CLINICAL ONCOLOGY 23 (33): 8520-8530 Tefferi A Pathogenesis of myelofibrosis with myeloid metaplasia | 3 | 5 |
| 7 | 2 | 200 | 103 2006 CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 57 (2): 145-164 Walz C; Sattler M Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML) | 0 | 1 |
| 8 | 3 | 198 | 106 2006 CURRENT PHARMACEUTICAL BIOTECHNOLOGY 7 (3): 185-198 Oveland E; Fladmark KE; Wergeland L; Gjertsen BT; Hovland R Proteomics approaches to elucidate oncogenic tyrosine kinase signaling in myeloid malignancies | 0 | 0 |
| 9 | 3 | 191 | 52 2005 SEMINARS IN HEMATOLOGY 42 (4): 206-220 Tefferi A; Spivak JL Polycythemia vera: Scientific advances and current practice | 6 | 7 |
| 10 | 1 | 189 | 36 2005 JOURNAL OF CLINICAL ONCOLOGY 23 (26): 6285-6295 Frohling S; Scholl C; Gilliland DG; Levine RL Genetics of myeloid malignancies: Pathogenetic and clinical implications | 2 | 14 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 11 | 24 | 185 | 148 2006 SEMINARS IN THROMBOSIS AND HEMOSTASIS 32 (3): 174-207 Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; et al. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: Therapeutic implications | 2 | 3 |
| 12 | 5 | 181 | 135 2006 LEUKEMIA & LYMPHOMA 47 (3): 381-396 Thiele J; Kvasnicka HM A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders | 2 | 4 |
| 13 | 1 | 178 | 25 2005 HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 90 (7): 949-968 Chalandon Y; Schwaller J Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies | 0 | 5 |
| 14 | 1 | 175 | 43 2005 MAYO CLINIC PROCEEDINGS 80 (7): 947-958 Tefferi A; Gilliland DG The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Status report and immediate implications for disease classification and diagnosis | 16 | 24 |
| 15 | 7 | 173 | 138 2006 MAYO CLINIC PROCEEDINGS 81 (4): 553-563 Tefferi A; Elliot MA; Pardanani A Atypical myeloproliferative disorders: Diagnosis and management | 0 | 0 |
| 16 | 27 | 152 | 67 2006 ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE 130 (8): 1126-1132 Cao M; Olsen RJ; Zu YL Polycythemia vera - New clinicopathologic perspectives | 0 | 0 |
| 17 | 1 | 148 | 104 2006 CURRENT CANCER DRUG TARGETS 6 (2): 107-121 Klampfer L Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs | 0 | 0 |
| 18 | 10 | 148 | 150 2006 SEMINARS IN THROMBOSIS AND HEMOSTASIS 32 (3): 219-230 Thiele J; Kvasnicka HM Clinicopathological criteria for differential diagnosis of thrombocythemias in various myeloproliferative disorders | 0 | 1 |
| 19 | 5 | 143 | 133 2006 LEUKEMIA & LYMPHOMA 47 (2): 177-194 Nelson ME; Steensma DP JAK2 V617F in myeloid disorders: What do we know now, and where are we headed? | 2 | 5 |
| 20 | 1 | 129 | 26 2005 HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 90 (8): 1116-1127 De Keersmaecker K; Marynen P; Cools J Genetic insights in the pathogenesis of T-cell acute lymphoblastic leukemia | 0 | 5 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 21 | 11 | 129 | 156 2006 SEMINARS IN THROMBOSIS AND HEMOSTASIS 32 (4): 381-398 Bellucci S; Michiels JJ The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia | 0 | 0 |
| 22 | 1 | 121 | 74 2006 BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY 19 (3): 455-469 Tefferi A The diagnosis of polycythemia vera: New tests and old dictums | 0 | 0 |
| 23 | 1 | 118 | 57 2005 SEMINARS IN ONCOLOGY 32 (4): 422-431 Odenike O; Tefferi A Conventional and new treatment options for myelofibrosis with myeloid metaplasia | 0 | 0 |
| 24 | 2 | 115 | 114 2006 HEMATOLOGICAL ONCOLOGY 24 (2): 56-63 Reilly JT Idiopathic myelofibrosis: pathogenesis to treatment | 0 | 0 |
| 25 | 1 | 109 | 51 2005 SEMINARS IN HEMATOLOGY 42 (4): 196-205 Bench AJ; Pahl HL Chromosomal abnormalities and molecular markers in myeloproliferative disorders | 4 | 6 |
| 26 | 2 | 108 | 35 2005 JOURNAL OF CLINICAL INVESTIGATION 115 (12): 3339-3347 Kaushansky K The molecular mechanisms that control thrombopoiesis | 0 | 5 |
| 27 | 9 | 108 | 88 2006 BLOOD 107 (11): 4214-4222 Schafer AI Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia | 0 | 0 |
| 28 | 1 | 104 | 54 2005 SEMINARS IN HEMATOLOGY 42 (4): 248-258 Barosi G; Hoffman R Idiopathic myelofibrosis | 2 | 2 |
| 29 | 4 | 103 | 75 2006 BIOCHEMICAL PHARMACOLOGY 71 (6): 713-721 Valentino L; Pierre J JAW/STAT signal transduction: Regulators and implication in hematological malignancies | 1 | 2 |
| 30 | 5 | 101 | 68 2006 ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE 130 (8): 1133-1143 Ahmed A; Chang CC Chronic idiopathic myelofibrosis - Clinicopathologic features, pathogenesis, and prognosis | 0 | 0 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 31 | 1 | 98 | 144 2006 PHARMACOGENOMICS 7 (4): 597-612 Ma PC; Zhang XD; Wang ZHJ High-throughput mutational analysis of the human cancer genome | 0 | 0 |
| 32 | 1 | 94 | 29 2005 INTERNATIONAL JOURNAL OF HEMATOLOGY 82 (2): 93-99 Choudhary C; Muller-Tidow C; Berdel WE; Serve H Signal transduction of oncogenic Flt3 | 0 | 1 |
| 33 | 9 | 94 | 69 2006 ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE 130 (8): 1144-1150 Sanchez S; Ewton A Essential thrombocythemia - A review of diagnostic and pathologic features | 0 | 0 |
| 34 | 1 | 88 | 21 2005 DRUG RESISTANCE UPDATES 8 (3): 119-129 Cools J; Maertens C; Marynen P Resistance to tyrosine kinase inhibitors: Calling on extra forces | 0 | 2 |
| 35 | 1 | 86 | 59 2005 VIRCHOWS ARCHIV 447 (6): 909-919 Fend F; Bock O; Kremer M; Specht K; Quintanilla-Martinez L Ancillary techniques in bone marrow pathology: molecular diagnostics on bone marrow trephine biopsies | 1 | 2 |
| 36 | 3 | 85 | 53 2005 SEMINARS IN HEMATOLOGY 42 (4): 221-229 Zhao ZJ; Vainchenker W; Krantz SB; Casadevall N; Constantinescu SN Role of tyrosine kinases and phosphatases in Polycythemia vera | 2 | 3 |
| 37 | 1 | 84 | 34 2005 JOURNAL OF CLINICAL INVESTIGATION 115 (10): 2618-2624 Amaravadi R; Thompson CB The survival kinases Akt and Pim as potential pharmacological targets | 0 | 12 |
| 38 | 3 | 81 | 55 2005 SEMINARS IN HEMATOLOGY 42 (4): 266-273 Skoda R; Prchal JT Lessons from familial myeloproliferative disorders | 4 | 4 |
| 39 | 1 | 80 | 39 2005 LEUKEMIA 19 (10): 1739-1744 Delaval B; Lelievre H; Birnbaum D Myeloproliferative disorders: the centrosome connection | 0 | 3 |
| 40 | 1 | 80 | 92 2006 BLOOD 108 (1): 123-133 Liu Y; Pop R; Sadegh C; Brugnara C; Haase VH; et al. Suppression of Fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivo | 0 | 0 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 41 | 1 | 79 | 139 2006 MOLECULAR AND CELLULAR BIOLOGY 26 (11): 4052-4062 Mazurkiewicz-Munoz AM; Argetsinger LS; Kouadio JLK; Stensballe A; Jensen ON; et al. Phosphorylation of JAK2 at serine 523: a negative regulator of JAK2 that is stimulated by growth hormone and epidermal growth factor | 0 | 1 |
| 42 | 3 | 78 | 28 2005 HEMATOLOGY 10: 215-223 Michiels JJ Clinical, pathological and molecular features of the chronic myeloproliferative disorders: MPD 2005 and beyond | 3 | 4 |
| 43 | 2 | 74 | 11 2005 BLOOD 106 (13): 4102-4113 Martelli F; Ghinassi B; Panetta B; Alfani E; Gatta V; et al. Variegation of the phenotype induced by the Gatal(low) mutation in mice of different genetic backgrounds | 0 | 0 |
| 44 | 4 | 74 | 151 2006 SEMINARS IN THROMBOSIS AND HEMOSTASIS 32 (3): 251-259 Landolfi R; Di Gennaro L; Novarese L; Patrono C Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: Current insights and rationale for future studies | 0 | 0 |
| 45 | 1 | 72 | 73 2006 BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY 19 (3): 399-412 Chagraoui H; Wendling F; Vainchenker W Pathogenesis of myelofibrosis with myeloid metaplasia: Insight from mouse models | 0 | 0 |
| 46 | 2 | 72 | 77 2006 BLOOD 107 (3): 907-915 Zhao W; Kitidis C; Fleming MD; Lodish HF; Ghaffari S Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway | 0 | 3 |
| 47 | 2 | 72 | 110 2006 GROWTH FACTORS 24 (1): 89-95 Ingley E; Klinken SP Cross-regulation of JAK and Src kinases | 0 | 0 |
| 48 | 1 | 69 | 20 2005 DRUG NEWS & PERSPECTIVES 18 (5): 305-310 Thompson JE JAK protein kinase inhibitors | 1 | 3 |
| 49 | 6 | 69 | 58 2005 TRENDS IN MOLECULAR MEDICINE 11 (12): 546-554 James C; Ugo V; Casadevall N; Constantinescu SN; Vainchenker W A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects | 8 | 9 |
| 50 | 7 | 69 | 123 2006 LEUKEMIA 20 (2): 200-205 De Keersmaecker K; Cools J Chronic myeloproliferative disorders: a tyrosine kinase tale | 2 | 4 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 51 | 28 | 69 | 155 2006 SEMINARS IN THROMBOSIS AND HEMOSTASIS 32 (4): 341-351 Villeval JL; James C; Pisani DF; Casadevall N; Vainchenker W New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients | 0 | 0 |
| 52 | 3 | 68 | 66 2006 ANNALS OF HEMATOLOGY 85 (4): 226-232 Thiele J; Kvasnicka HM Grade of bone marrow fibrosis is associated with relevant hematological findings - a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis | 0 | 0 |
| 53 | 1 | 66 | 76 2006 BLOOD 107 (1): 176-183 Lucet IS; Fantino E; Styles M; Bamert R; Patel O; et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor | 2 | 4 |
| 54 | 5 | 66 | 101 2006 CANCER CELL 10 (1): 65-75 Walters DK; Mercher T; Gu TL; O'Hare T; Tyner JW; et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia | 0 | 0 |
| 55 | 11 | 63 | 128 2006 LEUKEMIA 20 (6): 971-978 Steensma DP; McClure RF; Karp JE; Tefferi A; Lasho TL; et al. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained | 1 | 1 |
| 56 | 1 | 61 | 32 2005 JOURNAL OF BIOLOGICAL CHEMISTRY 280 (29): 27251-27261 Royer Y; Staerk J; Costuleanu M; Courtoy PJ; Constantinescu SN Janus kinases affect thrombopoietin receptor cell surface localization and stability | 6 | 11 |
| 57 | 1 | 57 | 19 2005 CELL CYCLE 4 (8): 1053-1056 Tefferi A; Gilliland DG JAK2 in myeloproliferative disorders is not just another kinase | 8 | 12 |
| 58 | 3 | 57 | 91 2006 BLOOD 107 (12): 4898-4906 Hoelbl A; Kovacic B; Kerenyi MA; Simma O; Warsch W; et al. Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation | 0 | 0 |
| 59 | 1 | 54 | 102 2006 CANCER CELL 10 (1): 77-87 Kovacic B; Stoiber D; Moriggl R; Weisz E; Ott RG; et al. STAT1 acts as a tumor promoter for leukemia development | 0 | 0 |
| 60 | 1 | 52 | 2 2005 ARCHIVES OF INTERNAL MEDICINE 165 (22): 2651-2658 Chim CS; Kwong YL; Lie AKW; Ma SK; Chan CC; et al. Long-term outcome of 231 patients with essential thrombocythemia - Prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia | 1 | 2 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 61 | 3 | 52 | 16 2005 BRITISH JOURNAL OF HAEMATOLOGY 131 (3): 320-328 Tefferi A; Lasho TL; Schwager SM; Steensma DP; Mesa RA; et al. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates | 11 | 16 |
| 62 | 1 | 52 | 82 2006 BLOOD 107 (6): 2219-2222 Burkitt MJ; Raafat A Nitric oxide generation from hydroxyurea: significance and implications for leukemogenesis in the management of myeloproliferative disorders | 0 | 1 |
| 63 | 3 | 52 | 85 2006 BLOOD 107 (9): 3495-3502 Zeuner A; Pedini F; Signore M; Ruscio G; Messina C; et al. Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells | 1 | 1 |
| 64 | 1 | 51 | 142 2006 ONCOGENE 25 (33): 4573-4584 Joliot V; Cormier F; Medyouf H; Alcalde H; Ghysdael J Constitutive STAT5 activation specifically cooperates with the loss of p53 function in B-cell lymphomagenesis | 0 | 0 |
| 65 | 2 | 51 | 152 2006 SEMINARS IN THROMBOSIS AND HEMOSTASIS 32 (3): 267-275 Lengfelder E; Merx K; Hehlmann R Diagnosis and therapy of polycythemia vera | 0 | 0 |
| 66 | 0 | 50 | 17 2005 CANCER CELL 7 (4): 387-397 Levine RL; Wadleigh M; Cools J; Ebert BL; Wernig G; et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis | 156 | 156 |
| 67 | 1 | 48 | 4 2005 BLOOD 106 (6): 2162-2168 Jones AV; Kreil S; Zoi K; Waghorn K; Curtis C; et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders | 49 | 56 |
| 68 | 9 | 47 | 147 2006 REVUE DE MEDECINE INTERNE 27 (6): 473-477 Marie I; Herve F Mutation of protein kinase JAK2 in polycythemia vera: new perspectives in physiopathology and therapy | 0 | 0 |
| 69 | 1 | 46 | 105 2006 CURRENT OPINION IN ONCOLOGY 18 (1): 62-68 Taki T; Taniwaki M Chromosomal translocations in cancer and their relevance for therapy | 0 | 0 |
| 70 | 1 | 45 | 90 2006 BLOOD 107 (11): 4326-4333 Wierenga ATJ; Schepers H; Moore MAS; Vellenga E; Schuringa JJ STAT5-induced self-renewal and impaired myelopoiesis of human hematopoietic stem/progenitor cells involves down-modulation of C/EBP alpha | 0 | 0 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 71 | 1 | 45 | 117 2006 JOURNAL OF IMMUNOLOGY 176 (11): 6425-6433 Wagner-Ballon O; Chagraoui H; Prina E; Tulliez M; Milon G; et al. Monocyte/macrophage dysfunctions do not impair the promotion of myelofibrosis by high levels of thrombopoietin | 0 | 0 |
| 72 | 4 | 44 | 72 2006 BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY 19 (3): 387-397 Chen G; Prchal JT Polycythemia vera and its molecular basis: An update | 0 | 0 |
| 73 | 1 | 43 | 149 2006 SEMINARS IN THROMBOSIS AND HEMOSTASIS 32 (3): 208-218 Briere JB Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: Diagnosis and management | 0 | 0 |
| 74 | 1 | 42 | 1 2005 AMERICAN JOURNAL OF PATHOLOGY 167 (3): 849-858 Vannucchi AM; Pancrazzi A; Guglielmelli P; Di Lollo S; Bogani C; et al. Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis | 3 | 3 |
| 75 | 4 | 42 | 116 2006 JOURNAL OF BIOLOGICAL CHEMISTRY 281 (26): 18177-18183 Walz C; Crowley BJ; Hudon HE; Gramlich JL; Neuberg DS; et al. Activated Jak2 with the V617F point mutation promotes G(1)/S phase transition | 0 | 0 |
| 76 | 2 | 41 | 33 2005 JOURNAL OF BIOLOGICAL CHEMISTRY 280 (51): 41893-41899 Staerk J; Kallin A; Demoulin JB; Vainchenker W; Constantinescu SN JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation - Cross-talk with IGF1 receptor | 8 | 9 |
| 77 | 3 | 41 | 157 2006 SEMINARS IN THROMBOSIS AND HEMOSTASIS 32 (4): 417-421 Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; et al. Long-term incidence of hematological evolution in three french prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia | 0 | 0 |
| 78 | 2 | 39 | 45 2005 MOLECULAR INTERVENTIONS 5 (4): 211-215 Pesu M; O'Shea J; Hennighausen L; Silvennoinen O Identification of an acquired mutation in Jak2 provides molecular insights into the pathogenesis of myeloproliferative disorders | 3 | 3 |
| 79 | 2 | 39 | 146 2006 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 103 (16): 6224-6229 Jamieson CHM; Gotlib J; Durocher JA; Chao MP; Mariappan MR; et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation | 2 | 2 |
| 80 | 5 | 38 | 64 2006 AMERICAN JOURNAL OF PATHOLOGY 169 (2): 471-481 Bock O; Neuse J; Hussein K; Brakensiek K; Buesche G; et al. Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status | 0 | 0 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 81 | 1 | 36 | 24 2005 HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 90 (7): 871-874 Cazzola M; Skoda R Gain of function, loss of control - A molecular basis for chronic myeloproliferative disorders | 8 | 8 |
| 82 | 2 | 36 | 49 2005 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 102 (52): 18962-18967 Lu XH; Levine R; Tong W; Wernig G; Pikman Y; et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation | 8 | 9 |
| 83 | 4 | 36 | 112 2006 HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 91 (2): 169-175 Arellano-Rodrigo E; Alvarez-Larran A; Reverter JC; Villamor N; Colomer D; et al. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status | 3 | 3 |
| 84 | 8 | 36 | 145 2006 PLOS MEDICINE 3 (7): Art. No. E270 Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; et al. MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia | 0 | 0 |
| 85 | 4 | 35 | 65 2006 ANNALES DE BIOLOGIE CLINIQUE 64 (1): 3-9 Pargade V; Darnige L; Gaussem P Acquired mutation of JAK2 tyrosine kinase and polycythaemia vera | 0 | 0 |
| 86 | 2 | 35 | 153 2006 SEMINARS IN THROMBOSIS AND HEMOSTASIS 32 (3): 283-288 Harrison CN Management of essential thrombocythemia: Implications of the Medical Research Council Primary Thrombocythemia 1 trial | 0 | 1 |
| 87 | 5 | 34 | 86 2006 BLOOD 107 (9): 3676-3682 Passamonti F; Rumi E; Pietra D; Della Porta MG; Boveri E; et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34(+) cells into peripheral blood in myeloproliferative disorders | 4 | 4 |
| 88 | 2 | 34 | 109 2006 GASTROENTEROLOGY 130 (7): 2031-2038 Patel RK; Lea NC; Heneghan MA; Westwood NB; Milojkovic D; et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome | 0 | 0 |
| 89 | 19 | 34 | 111 2006 HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 91 (2): 159-161 Cazzola M; Passamonti F Not just clonal expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders | 0 | 0 |
| 90 | 20 | 34 | 136 2006 LEUKEMIA RESEARCH 30 (6): 739-744 Tefferi A; Pardanani A Mutation screening for JAK2(V617F): When to order the test and how to interpret the results | 1 | 2 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 91 | 1 | 32 | 31 2005 JOURNAL OF BIOLOGICAL CHEMISTRY 280 (24): 22788-22792 Zhao RX; Xing S; Li Z; Fu XQ; Li QS; et al. Identification of an acquired JAK2 mutation in Polycythemia vera | 52 | 56 |
| 92 | 1 | 32 | 100 2006 CANCER 107 (3): 451-458 Silver RT Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha | 0 | 0 |
| 93 | 1 | 31 | 60 2005 VIRCHOWS ARCHIV 447 (6): 947-953 Siebolts U; Ates M; Spitz R; Thiele J; Wickenhauser C Quantification of clonal hematopoiesis in polycythemia vera | 0 | 0 |
| 94 | 6 | 31 | 93 2006 BLOOD 108 (1): 346-352 Bellanne-Chantelot C; Chaumarel I; Labopin M; Bellanger F; Barbu V; et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders | 0 | 0 |
| 95 | 2 | 31 | 97 2006 CANCER 106 (3): 623-630 Dingli D; Schwager SM; Mesa RA; Li CY; Tefferi A Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia - A simple CBC-based scoring system | 0 | 1 |
| 96 | 2 | 30 | 15 2005 BRITISH JOURNAL OF HAEMATOLOGY 131 (2): 208-213 Wolanskyj AP; Lasho TL; Schwager SM; McClure RF; Wadleigh M; et al. JAK2(V617F) mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance | 19 | 25 |
| 97 | 1 | 29 | 22 2005 EXPERIMENTAL HEMATOLOGY 33 (11): 1299-1308 Corre-Buscail I; Pineau D; Boissinot M; Hermouet S Erythropoietin-independent erythroid colony formation by bone marrow progenitors exposed to interleukin-11 and interleukin-8 | 0 | 0 |
| 98 | 3 | 29 | 38 2005 LANCET 366 (9501): 1945-1953 Campbell PJ; Scott LM; Buck G; Wheatley K; East CL; et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study | 15 | 25 |
| 99 | 1 | 29 | 70 2006 BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY 19 (3): 361-364 Tefferi A Classic and atypical myeloproliferative disorders - Preface | 0 | 0 |
| 100 | 3 | 28 | 50 2005 SEMINARS IN HEMATOLOGY 42 (4): 181-183 Skoda R; Prchal JT Chronic myeloproliferative disorders - Introduction | 2 | 2 |
Page 1 of 2: [ 1 2 ]
Generated by HistCite 2006.08.14